Bio-Gene Technology Limited (BGT.AX)
AUD 0.03
(8.0%)
AUD 0.03
(8.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -709.55 Thousand AUD | 26.11% |
| 2023 | -2.99 Million AUD | 52.84% |
| 2022 | -6.34 Million AUD | -61.24% |
| 2021 | -3.93 Million AUD | 28.62% |
| 2020 | -5.51 Million AUD | -22.47% |
| 2019 | -4.49 Million AUD | 32.91% |
| 2018 | -6.7 Million AUD | 22.4% |
| 2017 | -8.64 Million AUD | -8402.92% |
| 2016 | -101.64 Thousand AUD | 51.32% |
| 2015 | -208.81 Thousand AUD | -307.35% |
| 2014 | -51.26 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -2.2 Million AUD | 0.0% |
| 2024 Q2 | -1.72 Million AUD | 0.0% |
| 2024 FY | -709.55 Thousand AUD | 76.27% |
| 2023 Q2 | -4.25 Million AUD | 0.0% |
| 2023 Q4 | -2.99 Million AUD | 0.0% |
| 2023 FY | -2.99 Million AUD | 52.84% |
| 2022 Q4 | -6.34 Million AUD | 0.0% |
| 2022 FY | -6.34 Million AUD | -61.24% |
| 2022 Q2 | -5.74 Million AUD | 0.0% |
| 2021 Q2 | -598.73 Thousand AUD | 0.0% |
| 2021 FY | -3.93 Million AUD | 28.62% |
| 2021 Q4 | -3.93 Million AUD | 0.0% |
| 2020 Q4 | -5.51 Million AUD | 0.0% |
| 2020 FY | -5.51 Million AUD | -22.47% |
| 2020 Q2 | -3.61 Million AUD | 0.0% |
| 2019 FY | -4.49 Million AUD | 32.91% |
| 2019 Q4 | -4.49 Million AUD | 0.0% |
| 2019 Q2 | -5.31 Million AUD | 0.0% |
| 2018 Q2 | -7.68 Million AUD | 0.0% |
| 2018 FY | -6.7 Million AUD | 22.4% |
| 2018 Q4 | -6.7 Million AUD | 0.0% |
| 2017 Q4 | -2.86 Million AUD | 0.0% |
| 2017 FY | -8.64 Million AUD | -8402.92% |
| 2016 FY | -101.64 Thousand AUD | 51.32% |
| 2015 FY | -208.81 Thousand AUD | -307.35% |
| 2014 FY | -51.26 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | 16.046% |
| Acrux Limited | -1.45 Million AUD | 51.333% |
| Actinogen Medical Limited | -9.13 Million AUD | 92.23% |
| AnteoTech Limited | -5 Million AUD | 85.813% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 95.541% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 94.419% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 27.751% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 94.314% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 61.09% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 86.686% |
| Biome Australia Limited | -1.56 Million AUD | 54.597% |
| Biotron Limited | -386.06 Thousand AUD | -83.791% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 99.105% |
| BTC Health Limited | -2.02 Million AUD | 64.911% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 76.759% |
| CSL Limited | 15.76 Billion AUD | 100.005% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 99.48% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.612% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 88.566% |
| Dimerix Limited | -21.99 Million AUD | 96.774% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 96.245% |
| Hexima Limited | -2.22 Million AUD | 68.127% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 42.704% |
| Immuron Limited | -11.48 Million AUD | 93.821% |
| Immutep Limited | -122.18 Million AUD | 99.419% |
| Imugene Limited | -91.56 Million AUD | 99.225% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 88.223% |
| Memphasys Limited | 4.13 Million AUD | 117.158% |
| Nanollose Limited | -96.22 Thousand AUD | -637.395% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 95.849% |
| Noxopharm Limited | -2.31 Million AUD | 69.415% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 85.677% |
| Nyrada Inc. | -4.76 Million AUD | 85.123% |
| Orthocell Limited | -19.92 Million AUD | 96.439% |
| PharmAust Limited | -9.71 Million AUD | 92.696% |
| Patrys Limited | -2.24 Million AUD | 68.333% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 95.964% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 88.78% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 93.018% |
| PYC Therapeutics Limited | -65.76 Million AUD | 98.921% |
| Race Oncology Limited | -17.18 Million AUD | 95.872% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 96.18% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 79.107% |
| Starpharma Holdings Limited | -19.83 Million AUD | 96.422% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 99.329% |
| Tissue Repair Ltd | -16.44 Million AUD | 95.684% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 114.003% |